Endpoint Enabling Study in Cyclin-dependent kinase-like 5 Deficiency Disorder (CDD)

Summary

The study is designed to identify the best outcome measures in assessing their suitability and the adaptability across a variety of countries and languages for future international clinical
trials for patients with CDD.

Eligibility

Currently recruiting participants: Yes

Eligible ages: 0 to 17

Inclusion criteria:

Patients ages newborn to 17 years old with documented diagnosis of CDKL5 deficiency

Exclusion criteria:

Any condition that, in the opinion of the investigator, would put the patient at
undue risk or make it unsafe for the patient to participate

Participate

Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

Dr. Julia Jacobs-LeVan at 4039552480 or Julia.Jacobs-LeVan@albertahealthservices.ca

Principal investigator:

Julia Jacobs-Levan

Clinical trial:

Yes

REB-ID:

REB22-0797